Update in medical treatment of Crohn's disease

Journal of Clinical Gastroenterology

Volumn 31, Issue 4, 2000, Pages 282-291

  Regueiro, Miguel D ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Crohn's disease; Inflammatory bowel disease; Treatment

Indexed keywords

ALICAFORSEN; ANTIBIOTIC AGENT; AZATHIOPRINE; BALSALAZIDE; BUDESONIDE; CIPROFLOXACIN; CORTICOSTEROID; CYCLOSPORIN; IMMUNOMODULATING AGENT; INFLIXIMAB; LANSOPRAZOLE; LIPOXYGENASE INHIBITOR; MERCAPTOPURINE; MESALAZINE; METRONIDAZOLE; OLSALAZINE; OMEPRAZOLE; PROTON PUMP INHIBITOR; RECOMBINANT INTERLEUKIN 10; RECOMBINANT INTERLEUKIN 11; THALIDOMIDE;

CLINICAL FEATURE; CLINICAL TRIAL; CROHN DISEASE; DRUG EFFICACY; DRUG MECHANISM; FISTULA; HUMAN; HYPERTENSION; IMMUNOMODULATION; NEPHROTOXICITY; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; REMISSION; REVIEW;

ALGORITHMS; CROHN DISEASE; HUMANS;

EID: 0033657834     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004836-200012000-00004     Document Type: Review

References (116)

1. Inflammatory bowel disease (1)
2. Prognosis of inflammatory bowel disease
3. Biologic therapy for inflammatory bowel disease
4. Novel therapies for inflammatory bowel disease
5. Salazopyrin, a new sulfanilamide preparation
6. Sulfasalazine: II. Some notes on the discovery and development of salazopyrin
7. Review article: The mode of action of the aminosalicylates in inflammatory bowel disease
8. Effects of suphasalazine and its metabolites on prostaglandin synthesis, inactivation and actions on smooth muscle
9. Metabolism of arachidonic acid in acetic acid colitis in rats: Similarity to human inflammatory bowel disease
10. 5-Aminosalicylic acid abrogates blood mononuclear cells
11. Inhibition of antibody secretion by 5-aminosalicylc acid
12. National Cooperative Crohn's Disease Study: Results of drug treatment
13. European Cooperative Crohn's Disease Study (ECCDS): Results of drug treatment
14. Postoperative recurrence of Crohn's disease in relation to radicality of operation and sulfasalazine prophylaxis: A multicenter trial
15. Multicentre trial: Sulfasalazine in asymptomatic Crohn's disease
16. Postoperative treatment with corticosteroids and salazosulphapyridine after radical resection for Crohn's disease
17. Mesalamine capsules for the treatment of active Crohn's disease: Results of a 16-week trial. Pentasa Crohn's Disease Study Group
18. A randomized, doubleblind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn's colitis and ileocolitis
19. Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: A multicenter placebo-controlled study. The Group d-Etdes Therapeutiques des Affections Inflammatories Digestives (GETA1D)
20. Oral 5-aminosalicyic acid (Asal) in the maintenance treatment of Crohn's disease. The Italian 1BD Study Group
21. Mesalamine in the maintenance treatment of Crohn's disease: A meta-analysis adjusted for confounding variables
22. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European cooperative Crohn's disease study VI
23. Frequency of glucocorticoid resistance and dependency in Crohn's disease
24. Molecular mechanisms involved in the regulation of prostaglandin biosynthesis by glucocorticoids
25. Novel pathways for glucocorticoid effects on neutrophils in chronic inflammation
26. Modulation by cytokines of glucocorticoid action
27. New therapeutic agents
28. Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group
29. A comparison of budesonide with predhisolone for active Crohn's disease
30. Oral budesonide as maintenance treatment for Crohn's disease: A placebo-controlled, dose ranging study. Canadian Inflammatory Bowel Disease Study Group
31. Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn's disease. The Budesonide Study Group
32. Is there a role for antibiotics as primary therapy in Crohn's ileitis?
33. Radiologic and clinical assessment of broad spectrum antibiotic therapy in Crohn's disease
34. Inhibition of delayed hypersensitivity by metronidazole and misonidazole
35. Immunomodulatory action of levofloxacin on cytokine production by human peripheral blood mononuclear cells
36. A comparative study of metronidazole and sulfasalazine for active Crohn's disease: The cooperative Crohn's disease study in Sweden
37. Double blind, placebo controlled trial of metronidazole in Crohn's disease
38. Healing of perineal Crohn's disease with metronidazole
39. Metronidazole therapy for Crohn's disease and associated fistulae
40. Metronidazole therapy for perineal Crohn's disease: A follow up study
41. Cutaneous metastatic Crohn's disease: Treatment with metronidazole
42. Metastatic Crohn's disease responding to metronidazole
43. Controlled trail of metronidazole treatment for prevention of Crohn's recurrence after ileal resection
44. Ciprofloxacin may be useful in Crohn's disease
45. Long-term outcome of ciprofloxacin treatment in severe perianal or fistulous Crohn's disease
46. A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease
47. Use of antibiotics in the treatment of active Crohn's disease: Experience with metronidazole and ciprofloxacin
48. Combination ciprofloxacin and metronidazole for active Crohn's disease
49. A review of immune modifier therapy for inflammatory bowel disease: Azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate
50. Azathioprine: State of the art in inflammatory bowel disease
51. Azathioprine metabolism: Pharmacokinetics of 6-mercaptopurine, 6-thiouric acid and 6-thioguanine nucleotides in renal transplant patients
52. Controlled trial of azathioprine in Crohn's disease
53. Treatment of Crohn's disease with azathioprine: A controlled evaluation
54. Azathioprine has a very limited role in the treatment of Crohn's disease
55. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study
56. Azathioprine and 6-mercaptopurine in Crohn's disease. A meta-analysis
57. Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group
58. Immunosuppressant therapy of inflammatory bowel disease: Pharmacologic and clinical aspects
59. Use of azathioprine or 6-mercaptopurine in the treatment of Crohn's disease
60. Favorable effect of 6-mercaptopurine on fistulae of Crohn's disease
61. Management of bladder fistulas in Crohn's disease
62. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine
63. Post-operative with 6-MP, 5-ASA or placebo in Crohn's disease. A 2-year multicenter trial
64. 6-Mercaptopurine in the management of inflammatory bowel disease: Short- and long-term toxicity
65. The role of leukopenia in the 6-mercaptopurine-induced remission of refractory Crohn's disease
66. Pharmacogenomics and metabolite measurement for 6-Mercaptopurine therapy in inflammatory bowel disease
67. 6-Mercaptopurine metabolism in Crohn's disease: Correlation with efficacy and toxicity
68. Quantitation of 6-thioguanine in peripheral blood leukocyte DNA in Crohn's disease patients on maintenance 6-mercaptopurine therapy
69. Azathioprine metabolite levels predict clinical responsiveness to therapy in IBD
70. Pharmacogenetics of acute azathioprine toxicity: Relationship to thiopurine methyl-transferase genetic polymorphism
71. Mercaptopurine pharmacogenetics; monogeneic inheritance of erythrocyte thiopurine methyl-transferase activity
72. Folate status of rheumatoid arthritis patients receiving long-term low dose methotrexate therapy
73. Molecular and cellular effects of methotrexate
74. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease
75. Long-term use of methotrexate in inflammatory bowel disease: Severe disease 3, drug therapy 2: Seventh inning stretch
76. Methotrexate for the treatment of Crohn's disease
77. Low-dose oral methotrexate in refractory inflammatory bowel disease
78. Methotrexate for inflammatory bowel disease: Pharmacology and preliminary results
79. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease
80. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis
81. Cyclosporine in severe ulcerative colitis refractory to steroid therapy
82. Cyclosporine
83. Immunosuppressive agents: Recent developments in molecular action and clinical application
84. A placebo-controlled, doubleblind randomized trial of cyclosporine therapy in active Crohn's disease
85. Low-dose cyclosporine for the treatment of Crohn's disease
86. Rapid closure of Crohn's disease fistulas with continuous intravenous cyclosporin A
87. A critical review of cyclosporine therapy in inflammatory bowel disease
88. The mouse/human chimeric monoclonal antibody cA2 neutroalizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo
89. Chimeric anti-TNF monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions
90. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2)
91. A multicenter trial of cA2 anti-TNF chimeric monoclonal antibody in patients with actve Crohn's disease
92. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor at for Crohn's disease
93. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease
94. Infliximab for the treatment of fistulas in patients with Crohn's disease
95. Long-term safety of infliximab (anti-TNFa antibody) in patients with rheumatoid arthritis: Results of the ATTRACT trail
96. The relationship between infliximab treatment and lymphoma in Crohn's disease
97. Traffic signals for lymphocyte recirculation and leukocyte emigration
98. + T cells
99. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease
100. Interleukin-10 in the intestine
101. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease
102. Safety, tolerance and efficacy of multiple doses of subcutaneous interleukin-10 in mild to moderate active Crohn's disease (STEMM-CD)
103. A safety and efficacy study of recombinant human interleukin-10 (rHulL-10) treatment in 329 patients with chronic active Crohn's disease (CACD)
104. Protection of the small intestinal clonogenic stem cells from radiation-induced damage by pretreatment with interleukin 11 also increases murine survival time
105. Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease
106. A randomized, double-masked, placebo-controlled study of recombinant human interleukin eleven (rhlL-11) in Crohn's disease subjects not receiving prednisone
107. Short-chain fatty acids in ulcerative colitis
108. Fish oil fatty acid supplementation in active ulcerative colitis: A double-blind, placebo-controlled, crossover study
109. A randomized controlled study of evening primrose oil and fish oil in ulcerative colitis
110. Treatment of ulcerative colitis with fish oil supplementation: A prospective 12 month randomized controlled trial
111. Dietary supplementation with fish oil in ulcerative colitis
112. Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease
113. Studies on the anti-inflammatory properties of thalidomide: Effects on polymorphonuclear leukocytes and monocytes
114. Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent
115. Thalidomide therapy for patients with refractory Crohn's disease: An open-label trial
116. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease